Navigation Links
Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
Date:9/22/2008

Results and Preclinical Research at Upcoming Conferences

CALGARY, Sept. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced the participation of five of its collaborators and their schedule of presentations at four conferences through November 15, 2008 covering clinical trial results and preclinical research on REOLYSIN(R).

"It's an important time for Oncolytics as we begin to share additional results of our ongoing clinical trial and preclinical research programs for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is the results of these trials that should help us to determine the late-stage clinical path forward for REOLYSIN(R)."

Dr. Kevin Harrington and colleagues are scheduled to present a poster presentation entitled "Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting, being held in San Diego, California from October 31-November 2, 2008.

Prof. Hardev Pandha and colleagues are scheduled to present a poster presentation entitled "A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel to Patients with Advanced Malignancies" at the iSBTc annual meeting.

Dr. Monica Mita et al is scheduled to make two oral presentations, both entitled "A Phase II Study of Intravenous Reolysin (Wild Type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" at the Chemotherapy Foundation Symposium XXVI, being held in New York from November 4-8, 2008 and also at the Connective Tissue Oncology Society (CTOS) meeting, being held in London, U.K. from November 13-15, 2008.

Dr. Anders Kolb and colleagues are scheduled to deliver a poster presentation ent
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 - Elsevier, a world-leading provider of scientific, technical ... publication of a recent study in Reproductive ... showing that those with an abnormal chromosomal composition can ... developed to blastocysts, thereby classifying the risk of genetic ... same group has undertaken a retrospective study, using their ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... 11, 2012 Dr. Richard Dolinar, chairman of the ... of concern that the U.S. Food and Drug Administration ... the U.S. drug market in prepared testimony for the ... FDA,s recent draft guidelines for the development of biosimilar ...
... Calif., May 10, 2012 Aviir Diagnostic Laboratory has ... testing as a participating provider with Stratose Network and ... About Stratose A true pioneer of ... OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims) works ...
... 9, 2012 A monumental discovery that provides the promise ... at large was announced this morning in London during ... National Children,s Leukemia Foundation, a leading non-profit organisation in ... teams in the United States and Israel have discovered. ...
Cached Biology Technology:Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway 2Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3Founder of National Children's Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe 2Founder of National Children's Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe 3
(Date:5/16/2013)... For decades, scientists have used ancient shorelines to predict the ... Markings of a high shoreline from three million years ago, ... period were thought to be evidence of a high ... This assumption has led many scientists to think that if ... they may do just the same in our modern, progressively ...
(Date:5/16/2013)... and athletes choose to wear the color red when ... Psychological Science , a journal of the Association ... do with their testosterone levels. , The new study, ... of Sunderland and colleagues, demonstrated that males who chose ... higher testosterone levels than other males who chose blue. ...
(Date:5/16/2013)... where the entirety of an individual,s DNA is examined ... can cause health problems is a massively useful technology ... major ethical problems if used incorrectly, say new recommendations ... on line today (16 May 2013) in the ... on whole genome and on exome* sequencing and analysis ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2High-testosterone competitors more likely to choose red 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... drilling rig exploded on April 20, 2010, in the ... planetary sciences at the University of Tennessee, Knoxville, grabbed all ... the Louisiana coast. Engel and dozens of scientists ... they knew would be needed once the oil began spilling ...
... white LED bulbs, it turns out, suppresses melatonin 5 times ... bulbs that give off an orange-yellow light. "Just as there ... be regulations and rules for the pollution stemming from artificial ... of Haifa. , "White" light bulbs that emit light ...
... Quebec City, September 12, 2011A study presented today by Universit ... currently underway in Quebec City revealed that the risk of ... at least one member is an insomniac. The ... Laval,s School of Psychology, came to these conclusions following a ...
Cached Biology News:UT researcher investigates Deepwater Horizon oil spill impact on coast 2Dangers of exposure to 'white' light 2Dangers of exposure to 'white' light 3
... 100 Amplification Kit, 100 reactions. Prepare ... in 4-6 h.Generate microgram quantities of ... starting material.Use amplified DNA directly for ... bacterial or M13 liquid cultures, colonies, ...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: